LABP Profile
Landos Biopharma, Inc., operating as a clinical-stage biopharmaceutical firm, specializes in the discovery and advancement of oral therapeutics tailored for individuals grappling with autoimmune diseases. The company's foremost product candidate, omilancor, represents a gut-restricted oral therapeutic designed to target lanthionine synthetase C-like protein 2 (LANCL2), with applications in treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Additionally, Landos Biopharma is developing NX-13, another gut-restricted oral therapeutic aimed at NOD-like receptor X1 (NOD-like), a receptor associated with modulating inflammatory cytokines, with therapeutic potential for UC and CD. Further expanding its therapeutic arsenal, LABP-104, an orally-active small molecule therapeutic candidate, targets LANCL2 agonist for addressing systemic lupus erythematosus and rheumatoid arthritis (RA).
The company's preclinical pipeline encompasses a range of promising candidates. LABP-66, an oral small molecule NOD-like pathway agonist, holds promise for multiple sclerosis and Alzheimer's disease treatment. LABP-69, an oral PLXDC2 agonist, targets diabetic nephropathy and RA. LABP-73, an oral small molecule NLRX1 pathway agonist, is in development for asthma and chronic obstructive pulmonary disease. Lastly, LABP-111, an oral small molecule LANCL2 pathway agonist, holds potential in addressing nonalcoholic steatohepatitis and type 1 diabetes.
Founded in 2017 and headquartered in Blacksburg, Virginia, Landos Biopharma, Inc. remains comitted to pioneering innovative solutions to address the complexities of autoimmune diseases, leveraging its cutting-edge research and development efforts to improve patient outcomes and quality of life.
|
